CN104857059A - 一种治疗颈椎、腰椎疾病的中药组合物 - Google Patents
一种治疗颈椎、腰椎疾病的中药组合物 Download PDFInfo
- Publication number
- CN104857059A CN104857059A CN201510293171.2A CN201510293171A CN104857059A CN 104857059 A CN104857059 A CN 104857059A CN 201510293171 A CN201510293171 A CN 201510293171A CN 104857059 A CN104857059 A CN 104857059A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- olibanum
- rhizoma chuanxiong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000029761 vertebral disease Diseases 0.000 title abstract 2
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 9
- 239000004863 Frankincense Substances 0.000 claims abstract description 9
- 241000628997 Flos Species 0.000 claims description 8
- 241001057584 Myrrha Species 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 208000018650 Intervertebral disc disease Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 210000003205 muscle Anatomy 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 4
- 240000000031 Achyranthes bidentata Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000207977 Dipsacales Species 0.000 abstract 1
- 241000208689 Eucommia ulmoides Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000132171 Phryma leptostachya Species 0.000 abstract 1
- 235000019606 astringent taste Nutrition 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000012287 Prolapse Diseases 0.000 description 6
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000014674 injury Diseases 0.000 description 5
- 206010005963 Bone formation increased Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 238000000554 physical therapy Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000002513 Flank pain Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010050031 Muscle strain Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- ZQBMUHABRSEAIK-UXBLZVDNSA-N 1-[4-[(e)-3-phenylprop-2-enyl]piperazin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCN1C\C=C\C1=CC=CC=C1 ZQBMUHABRSEAIK-UXBLZVDNSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010056377 Bone tuberculosis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010052443 Myofascitis Diseases 0.000 description 1
- 208000028373 Neck injury Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- -1 antondin Chemical compound 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- YTLQFZVCLXFFRK-UHFFFAOYSA-N bendazol Chemical compound N=1C2=CC=CC=C2NC=1CC1=CC=CC=C1 YTLQFZVCLXFFRK-UHFFFAOYSA-N 0.000 description 1
- 229950000900 bendazol Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019669 cervical disc degenerative disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
公开了一种中药组合物,其技术特征为由乳香、没药、红花、牛膝、杜仲、透骨草、川芎、续断按固定比例组成,使用白酒做给药载体,热敷外用给药。该组合物具有舒筋活络、祛风散寒、收敛固涩、活血化瘀的功效,临床上对于颈椎、腰椎疾病有较好的治疗作用。
Description
技术领域
本发明属于中医药领域,涉及一种中药组合物,该组合物对于颈、腰椎增生及风湿有较好的治疗作用。
背景技术
临床上关于颈椎、腰椎疾病是中老年人的主要疾病,颈椎病又称颈椎综合征,是由于颈椎间盘退行性变、颈椎肥厚增生以及颈部损伤等引起颈椎骨质增生,或椎间盘脱出、韧带增厚,刺激或压迫颈脊髓、颈部神经、血管而产生一系列症状的临床综合征。主要表现为颈肩痛、头晕头痛、上肢麻木、肌肉萎缩、严重者双下肢痉挛、行走困难,甚至四肢麻痹,大小便障碍,出现瘫痪。多发在中老年人,男性发病率高于女性。腰椎病是多是因脊柱及脊柱周围软组织急慢性损伤或腰椎间盘退变、腰椎骨质增生等原因引起,在临床上表现为以腰痛、腰部活动受限和腰腿痛为主要症状的疾病。医学上所讲的腰椎病,涵盖了“腰部软组织劳损、腰部肌筋膜炎、腰椎退行性骨关节病、腰三横突综合征、腰椎间盘突出症、急性腰扭伤、梨状肌综合征、腰椎结核等”疾患。
颈椎、脊椎疾病的治疗包括物理治疗、药物治疗、手术治疗等多种方法。物理治疗包括按摩推拿、针灸、电疗、拔罐、激光、超声波、石蜡疗法等,此类疗法也主要以消炎止痛、活血化淤为主,有很好的治疗效果。由于腰椎病的病人多数伴随慢性腰肌劳损,梨状肌肉紧张,腰椎病物压迫的神经随神经走过的部位肌肉痉挛造成腰腿痛,一般医院会用理疗、推拿、针灸等治疗手段来缓解肌肉的紧张和痉挛。所以做过理疗的病人都知道,在做理疗时会舒服一点,不做后又会和从前一样。药物疗法主要有消炎消肿、止痛、活血化淤的作用,主要有:阿司匹林、消炎痛、布洛芬、芬必得、安痛定、扶他林(解热镇痛抗炎药),强痛定、痛力克(镇痛药),地巴唑复方丹参注射液(扩张血管药),维生素B1、B12、E、C、三磷酸腺苷、肌苷(维生素及营养药),中枢性肌肉松弛剂、利尿脱水药等。西药疗法并非治本之法,只能缓解症状,暂时减轻病人的痛苦,在病早期或急性期,效果必较明显。但化学药物均有不同程度的毒副作用,不宜长期服用,只能起到辅助作用,而中医可以标本兼治。手术治疗主要用于严重影响生活、工作和休息者,经非手术疗法无效者。手术改变了人体原有的组织结构,属于创伤性疗法。患者比较痛苦,手术破坏人体组织,造成人体组织结构的改变,容易增加其它组织的病变,比如,有些患者,在术后一段时间后,容易引发其它颈、腰间盘的退变或造成不同程度的膨出或突出,还容易产生神经沾连或腿脚麻木,失去知觉,尤其容易引发骨质增生或椎骨不稳。所以手术疗法只能在不得已时采用,腰突症在某种程度上属于自限性或自愈性疾病,应尽量选用保守疗法。
相对于西药的对标治疗,中医在对本治疗方面积累了丰富的经验。传统中药在这方面的研究也具有一定优势,能够从疾病整体出发,辨证论治。本发明提供一种中药组合物,能够克服现有药物治疗的缺陷,对于颈椎、脊椎疾病的治疗还是非常有效的。
技术内容
本发明的目的是提供一种中药组合物,该组合物具有舒筋活络、祛风散寒、收敛固涩、活血化瘀的功效,临床上对于颈椎、腰椎疾病有较好的治疗作用。
本发明的中药组合物由下述中药成分组成:乳香、没药、红花、牛膝、杜仲、透骨草、川芎、续断。
本发明的组合物所用的中药组分重量配比为:乳香7份、没药12份、红花9份、牛膝8份、杜仲15份、透骨草7份、川芎6份、续断11份。
本发明中药组合物的制用方法为:按比例称取乳香、没药、红花、牛膝、杜仲、透骨草、川芎、续断。加入药材总重20倍量的白酒(52°以上)密封浸泡15日以上备用。使用时取用药液加热45-50℃后用毛巾热敷,每30分钟一次。
本发明中药组合物所用各中药的药理学基础为:
乳香:治气血凝滞,心腹疼痛,痈疮肿毒,跌打损伤,痛经,产后瘀血刺痛。
没药:有活血止痛,消肿生肌等功效。
红花,味辛、性温,归心、肝经。气香行散,入血分具有活血通经,祛瘀止痛的功效。
牛膝,味苦、酸,性平。祛风药,活血祛瘀药。主要用于腰膝酸痛,下肢痿软,血滞经闭,痛经,产后血瘀腹痛,症瘕,胞衣不下,热淋,血淋,跌打损伤,痈肿恶疮,咽喉肿痛。
杜仲,补肝肾,壮腰膝,强筋骨,安胎的功效。杜仲对免疫系统,内分泌系统,中枢神经系统,循环系统和泌尿系统都有不同程度的调节作用,杜仲能兴奋垂体-肾上腺皮质系统,增强肾上腺皮质功能。
透骨草,祛风湿,活血,舒筋,止痛。治风湿痛,闪挫伤,无名肿毒,阴囊湿疹。
川芎,用于活血行气,祛风止痛,川芎辛温香燥,走而不守,既能行散,上行可达巅顶;又入血分,下行可达血海。活血祛瘀作用广泛,适宜瘀血阻滞各种病症;祛风止痛,效用甚佳,可治头风头痛、风湿痹痛等症。昔人谓川芎为血中之气药,殆言其寓辛散、解郁、通达、止痛等功能。
续断,续断的功效与作用主要表现在补肝肾,强筋骨,续折伤,止崩漏。续断一般用于治疗腰膝酸软,风湿痹痛,崩漏,胎漏,跌扑损伤。酒续断多用于风湿痹痛,跌扑损伤。盐续断多用于腰膝酸软。《本草求真》:川续断,实疏通气血筋骨第一药也。第因气薄而见精脱、胎动、溺血、失血等症,则又深忌,以性下流者故耳。
本发明所用药方并非为各类药材的简单组合,而是在考虑到各类药物的性质、口味、药性、配伍禁忌的基础上筛选出来的,并且按照一定配比组成的处方,各方各司其职,既有机配合,又相互促进。
本发明中药组合物使用白酒热敷,一方面是借用白酒的溶解能力最大限度提取有效成分,另一方面是白酒的载药穿透力,使药物在热白酒的作用下迅速被皮肤吸收,达到病灶,达到快速靶向给药的目的,尽量减少药物剂量,降低全身给药毒性。第三个方面是利用白酒的挥发性和消毒功效,药物制备使用安全,且药物吸收后白酒挥发,使皮肤局部冷却收口,避免病菌感染。
临床疗效
1.样本信息
自2009年6月到2014年9月,本发明中药组合物累计治疗颈椎、腰椎病患者46人,患者均系门诊确诊病人,其中男38人,女8人,年龄最大者63岁,最小者18岁。
2.疗效标准
痊愈:临床症状消失,血沉降至正常水平,一年内不复发。
显著:临床症状得到改善,或临床症状消失,但效果持续时间有限,一年内复发。
有效:临床症状大部分改善,疼痛程度明显减轻,疼痛次数减少,疼痛时间减短。
无效:临床症状无任何改变或恶化。
3.治疗方法
采用热敷给药,每日一至两次,十日为一个疗程。
4.样本病例
5.典型病例
(1)郑某某:男,31岁,己婚。2011年5月8日来诊,主诉;2010年3月份开始腰部疼痛经多方治疗得以缓解,2011年5月份开始腰部疼痛严重,前往第二医院CT检查诊断为腰椎间盘突出症,经第二医院治疗无效,后来长期理疗推拿等维持,2012年1月份经人介绍有个医腰椎间盘突出症的名医就前往就医,但去了就好来了又痛这样反复多次后又再次严重起来,颈部至颈椎胸椎腰椎全部僵硬活动受限。后来看到报纸广告陈李济活络止痛丸开始服用感觉效还可以,可是连续服用3个月多时间看来陈李济活络止痛丸不是纯中医制剂。2012年12月8日来诊时;颈部至颈椎胸椎腰椎全部僵硬活动受限,右膝部肿、左脚大拇趾次趾两踝关节红肿极痛,低烧体温38C度以下。余给予口头协议如你有耐心配合我能还你一个健康完整的身体,他己经清楚自己所患的是难治病坚定信心的积极配合治疗。给予本发明中药组合物药液热敷40天,痊愈。
(2)周某,男,52岁,腰椎间盘突出患者。腰椎突出压迫神经,无法行路。经服用本发明药液热敷34天后,恢复正常,外出打工无复发。
(3)王某,男,31岁,患腰椎间盘突出,翻不了身,下不了床,请我去出诊,使用本发明药液热敷治疗三个疗程,痊愈。
(4)林某某,颈椎病患者,男,42岁,头昏、眩晕、呕吐、看天旋转,来我处求治疗,使用本发明药液治疗2个疗程,痊愈,至今未复发。
具体实施例
取乳香70克、没药120克、红花90克、牛膝80克、杜仲150克、透骨草70克、川芎60克、续断110克。置于密闭瓦罐中,加入15公斤52°以上白酒,常温浸泡15日。备用。
使用时取用药液加热45-50℃后用毛巾热敷,每30分钟一次。每日一至两次,十日为一个疗程。
用药禁忌:皮肤过敏者慎用、皮肤溃烂者慎用。
Claims (3)
1.一种治疗颈椎、腰椎疾病的中药组合物,其技术特征在于该组合物由以下活性成分组成:乳香、没药、红花、牛膝、杜仲、透骨草、川芎、续断。
2.如权利要求1所述治疗颈椎、腰椎疾病的中药组合物,各活性成分的重量份配比为:乳香7份、没药12份、红花9份、牛膝8份、杜仲15份、透骨草7份、川芎6份、续断11份。
3.如权利要求1、2所述中药组合物,其制备及使用方法为:按比例称取乳香、没药、红花、牛膝、杜仲、透骨草、川芎、续断。加入药材总重20倍量的白酒(52°以上)密封浸泡15日以上备用。使用时取用药液加热45-50℃后用毛巾热敷,每30分钟一次。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510293171.2A CN104857059A (zh) | 2015-06-02 | 2015-06-02 | 一种治疗颈椎、腰椎疾病的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510293171.2A CN104857059A (zh) | 2015-06-02 | 2015-06-02 | 一种治疗颈椎、腰椎疾病的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104857059A true CN104857059A (zh) | 2015-08-26 |
Family
ID=53903526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510293171.2A Pending CN104857059A (zh) | 2015-06-02 | 2015-06-02 | 一种治疗颈椎、腰椎疾病的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104857059A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106177638A (zh) * | 2016-09-26 | 2016-12-07 | 四川聚豪生物科技有限公司 | 一种用于治疗颈腰椎疾病的中药组合物及制备方法 |
CN106377642A (zh) * | 2016-12-08 | 2017-02-08 | 肖训 | 一种治疗颈椎腰椎疾病的推拿按摩药酒 |
CN106421093A (zh) * | 2016-10-16 | 2017-02-22 | 成都兴倍加生物科技有限责任公司 | 一种可有效治疗颈椎和腰椎疾病的酊剂药物及制备方法 |
CN109260322A (zh) * | 2018-09-27 | 2019-01-25 | 郭心畅 | 植物精油 |
CN113144055A (zh) * | 2021-04-06 | 2021-07-23 | 崔文东 | 一种治疗颈椎病骨质增生的药丸 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN2249088Y (zh) * | 1995-09-15 | 1997-03-12 | 兰玉歧 | 治疗骨质增生膏药 |
CN1380098A (zh) * | 2002-05-20 | 2002-11-20 | 张勇飞 | 一种抗感染复合制剂及其制备方法 |
CN103494866A (zh) * | 2012-03-29 | 2014-01-08 | 海丝克(河南)生物科技有限公司 | 一种治疗腰腿疼的组配方法 |
CN104147075A (zh) * | 2014-08-15 | 2014-11-19 | 麻强 | 一种中药组合物及其制备方法和制药用途 |
CN104224978A (zh) * | 2013-06-24 | 2014-12-24 | 陈洪涛 | 腰椎骨质散 |
-
2015
- 2015-06-02 CN CN201510293171.2A patent/CN104857059A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN2249088Y (zh) * | 1995-09-15 | 1997-03-12 | 兰玉歧 | 治疗骨质增生膏药 |
CN1380098A (zh) * | 2002-05-20 | 2002-11-20 | 张勇飞 | 一种抗感染复合制剂及其制备方法 |
CN103494866A (zh) * | 2012-03-29 | 2014-01-08 | 海丝克(河南)生物科技有限公司 | 一种治疗腰腿疼的组配方法 |
CN104224978A (zh) * | 2013-06-24 | 2014-12-24 | 陈洪涛 | 腰椎骨质散 |
CN104147075A (zh) * | 2014-08-15 | 2014-11-19 | 麻强 | 一种中药组合物及其制备方法和制药用途 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106177638A (zh) * | 2016-09-26 | 2016-12-07 | 四川聚豪生物科技有限公司 | 一种用于治疗颈腰椎疾病的中药组合物及制备方法 |
CN106421093A (zh) * | 2016-10-16 | 2017-02-22 | 成都兴倍加生物科技有限责任公司 | 一种可有效治疗颈椎和腰椎疾病的酊剂药物及制备方法 |
CN106377642A (zh) * | 2016-12-08 | 2017-02-08 | 肖训 | 一种治疗颈椎腰椎疾病的推拿按摩药酒 |
CN109260322A (zh) * | 2018-09-27 | 2019-01-25 | 郭心畅 | 植物精油 |
CN113144055A (zh) * | 2021-04-06 | 2021-07-23 | 崔文东 | 一种治疗颈椎病骨质增生的药丸 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104644943A (zh) | 中药组合物、含该组合物的药灸及制备方法 | |
CN102908442B (zh) | 治疗跌打损伤的组合物及其药酒 | |
CN103463356B (zh) | 治疗阳虚痹症的中药组合物 | |
CN104189871A (zh) | 一种治疗骨质增生的药酒 | |
CN104857059A (zh) | 一种治疗颈椎、腰椎疾病的中药组合物 | |
CN104398603A (zh) | 颈椎腰椎腿关节中草药热敷治疗袋及其使用方法 | |
CN103239520A (zh) | 一种治疗骨性关节炎的回药膏及其制备方法 | |
CN101185672B (zh) | 一种内服用于治疗腰椎骨质增生的中药汤剂 | |
CN103599404B (zh) | 一种治疗颈椎病的中药汤剂 | |
CN103720851B (zh) | 一种治疗骨质增生的中药汤剂 | |
CN102342983B (zh) | 一种治疗腰腿疼痛的中药组合物及其制剂的制备方法 | |
CN102552862A (zh) | 一种治疗阳虚气滞血瘀型慢性盆腔炎的中药制备方法 | |
CN104547034A (zh) | 治疗骨质增生的中药制剂及其制备方法 | |
CN104027609A (zh) | 一种治疗风湿骨病、关节疼痛、肌肉损伤的膏药 | |
CN106362066A (zh) | 一种治疗风湿类风湿性疾病的药酒及其制备方法 | |
CN104258285A (zh) | 一种内服外用治疗腰椎骨质增生的药物及其制备方法 | |
CN104383175A (zh) | 一种用于治疗慢性骨髓炎的药物及制备方法 | |
CN106421255A (zh) | 一种外用中草药组合物及其应用 | |
CN104257965A (zh) | 一种内服外洗治疗膝关节骨质增生的中药及其制备方法 | |
CN105106521A (zh) | 一种跌打损伤止痛剂 | |
CN104547989A (zh) | 一种用于治疗脊椎病的藏药膏剂及其使用方法 | |
CN104644732B (zh) | 一种治疗肝肾不足型绝经后骨质疏松症的中药制剂 | |
CN104208531A (zh) | 一种治疗腰椎骨质增生的中药组合物 | |
CN110251600A (zh) | 一种骨康中药及其制备方法 | |
CN112915180A (zh) | 一种追风透骨膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150826 |